Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Niraparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 0.98 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 11/20 | 0.98 |
| ▸ | PARP3 | Q9Y6F1 | 10/20 | 0.98 |
| ▸ | TNKS | O95271 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.98 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.98 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.98 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.98 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.98 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.98 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.98 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niraparib SCHEMBL567839 | 1.00 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422061 | 1.00 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422151 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421952 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421875 | 0.99 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL28370623 | 0.98 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3737274 | 0.95 | PARP1 (0.92) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3737277 | 0.95 | PARP1 (0.92) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3740349 | 0.94 | PARP1 (0.91) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3659848 | 0.93 | PARP1 (0.89) | PARP1PARP2PARP3TNKSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | AGENDIA N V (NL) | 2026-04-23 | — | — | US | disclosed |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | AGENDIA, INC. | 2026-02-19 | — | — | US | disclosed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4482986-A1 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024263637-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240060138-A1 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-22 | — | — | US | disclosed |
| WO-2023224487-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | AGENDIA N.V. (NL) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224488-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | AGENDIA N.V. (NL) | 2023-11-23 | — | — | WO | disclosed |
| US-20230330223-A1 | TREATMENT OF HER2 NEGATIVE, MAMMAPRINT HIGH RISK 2 BREAST CANCER | AGENDIA N.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120289570-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS | NIH | 2012-11-15 | — | — | US | disclosed |
| US-20120035244-A1 | PARP1 TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-09 | — | — | US | disclosed |
| US-8071623-B2 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA | 2011-12-06 | — | — | US | disclosed |
| EP-2336120-A1 | Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) | 2011-06-22 | — | — | EP | disclosed |
| EP-2109608-B1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-03-23 | — | — | EP | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2109608-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2009-10-21 | — | — | EP | disclosed |
| WO-2008084261-A1 | AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2008-07-17 | — | — | WO | disclosed |
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | MERCK SHARP & DOHME LLC | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167345-A1 | Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885PARP3 4/4885 |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | BRCA1, PARP3, PARP2 | PARP1 4/4885PARP2 3/4885PARP3 2/4885 |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | PARP1 1/4885PARP2 6/4885PARP3 7/4885 |
| US-20120035244-A1 | PARP1 TARGETED THERAPY | PARP1, PARP11, PARP12 | PARP1 1/4885PARP2 4/4885PARP3 8/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | PARP1 1959/4885PARP2 1720/4885PARP3 2187/4885 |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | BRCA1, PDCD1, CD274 | PARP1 1484/4885PARP2 498/4885PARP3 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.